BSI-730, a bispecific antibody targeting HER2 and PD-L1 for the development of a first-in-class bispecific ADC

被引：0
|
作者：
Hao, Xiaoyao
Li, Hongyan
Liu, Xiaodong F.
Liu, Jinyu
Dai, Wenwen
Pan, Ying
Hu, Hui-Han
Li, Jun
Xia, Shukai
Lyu, Qun
Davis, Hugh M.
Chen, Mingjiu
Peng, Zeyu
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-3135
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3135
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Discovery of a common light chain bispecific antibody targeting PD-1 and PD-L1 by Hybridoma-to-Phage-to-Yeast (H2PtY) platform
    Liu, Peipei
    Gu, Chunyin
    Cao, Xiaodan
    Zhang, Huawei
    Wang, Zongda
    Yang, Yukun
    Ouyang, Kedong
    Zhen, Yingying
    Jia, Fangfang
    He, Xianqing
    Yu, Haixiang
    Deng, Sujun
    ANTIBODY THERAPEUTICS, 2024,
  • [42] Development of the Bispecific Antibody in Fab-scFv Format Based on an Antibody to Human Interferon Beta-1 and Antibody to HER2 Receptor
    Panina, A. A.
    Toporova, V. A.
    Rybchenko, V. S.
    Balabashin, D. S.
    Argentova, V. V.
    Yakimov, S. A.
    Solopova, O. N.
    Aliev, T. K.
    Dolgikh, D. A.
    Sveshnikov, P. G.
    Kirpichnikov, M. P.
    RUSSIAN JOURNAL OF BIOORGANIC CHEMISTRY, 2020, 46 (04) : 572 - 581
  • [43] Bispecific Antibody Approach for Improved Melanoma-Selective PD-L1 Immune Checkpoint Blockade
    Koopmans, Iris
    Hendriks, Mark A. J. M.
    van Ginkel, Robert J.
    Samplonius, Douwe F.
    Bremer, Edwin
    Helfrich, Wijnand
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2019, 139 (11) : 2343 - +
  • [44] Development of the Bispecific Antibody in Fab-scFv Format Based on an Antibody to Human Interferon Beta-1 and Antibody to HER2 Receptor
    A. A. Panina
    V. A. Toporova
    V. S. Rybchenko
    D. S. Balabashin
    V. V. Argentova
    S. A. Yakimov
    O. N. Solopova
    T. K. Aliev
    D. A. Dolgikh
    P. G. Sveshnikov
    M. P. Kirpichnikov
    Russian Journal of Bioorganic Chemistry, 2020, 46 : 572 - 581
  • [45] Prediction of pharmacokinetics and receptor occupancy of a bispecific antibody against CD40 and PD-L1
    Diakonova, Alexandra
    Demin, Oleg
    Shchelokov, Dmitry
    Demin, Oleg
    CANCER RESEARCH, 2022, 82 (12)
  • [46] PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity
    Jiang, Haiping
    Ni, Haiqing
    Zhang, Pan
    Guo, Xiaoli
    Wu, Min
    Shen, Haoran
    Wang, Jie
    Wu, Weiwei
    Wu, Zhihai
    Ding, Jiazheng
    Tang, Rong
    Zhou, Shuaixiang
    Chen, Bingliang
    Yu, Michael
    Jing, Hua
    Liu, Junjian
    ONCOIMMUNOLOGY, 2021, 10 (01):
  • [47] Immunomodulation of T- and NK-cell Responses by a Bispecific Antibody Targeting CD28 Homolog and PD-L1
    Ramaswamy, Madhu
    Kim, Taeil
    Jones, Des C.
    Ghadially, Hormas
    Mahmoud, Tamer, I
    Garcia, Andrew
    Browne, Gareth
    Zenonos, Zenon
    Puplampu-Dove, Yvonne
    Riggs, Jeffrey M.
    Bhat, Geetha K.
    Herbst, Ronald
    Schofield, Darren J.
    Carlesso, Gianluca
    CANCER IMMUNOLOGY RESEARCH, 2022, 10 (02) : 200 - 214
  • [48] Preclinical development of a first-in-class vaccine encoding HER2, Brachyury and CD40L for antibody enhanced tumor eradication
    Hinterberger, Maria
    Endt, Kathrin
    Bathke, Barbara
    Habjan, Matthias
    Heiseke, Alexander
    Schweneker, Marc
    Von Rohrscheidt, Julia
    Atay, Cigdem
    Chaplin, Paul
    Kalla, Markus
    Hausmann, Juergen
    Schmittwolf, Carolin
    Lauterbach, Henning
    Volkmann, Ariane
    Hochrein, Hubertus
    Medina-Echeverz, Jose
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [49] Preclinical development of a first-in-class vaccine encoding HER2, Brachyury and CD40L for antibody enhanced tumor eradication
    Maria Hinterberger
    Kathrin Endt
    Barbara Bathke
    Matthias Habjan
    Alexander Heiseke
    Marc Schweneker
    Julia Von Rohrscheidt
    Cigdem Atay
    Paul Chaplin
    Markus Kalla
    Jürgen Hausmann
    Carolin Schmittwolf
    Henning Lauterbach
    Ariane Volkmann
    Hubertus Hochrein
    José Medina-Echeverz
    Scientific Reports, 13
  • [50] Phase 1 trial safety and efficacy of ragistomig, a bispecific antibody targeting PD-L1 and 4-1BB, in advanced solid tumors
    Falchook, Gerald Steven
    LoRusso, Patricia
    Goldman, Jonathan W.
    El-Khoueiry, Anthony B.
    Tolcher, Anthony W.
    Xing, Yan
    Henry, Jason Timothy
    Keam, Bhumsuk
    Kim, Dong-Wan
    Kim, Tae-Yong
    Kim, Hye Ryun
    Hong, Min Hee
    Kim, Min Hwan
    Lee, Dae Ho
    Lee, SangMi
    Jeon, JuYeun
    Hayslip, John W.
    Xu, Cong
    Garon, Edward B.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345